Ken Griffin Lexicon Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$1.51 - $2.39 $35,787 - $56,643	-23,700 Reduced 55.5%	19,000 $29,000
Q2 2024 Aug 14, 2024	SELL	$1.54 - $2.28 $143,990 - $213,179	-93,500 Reduced 68.65%	42,700 $71,000
Q1 2024 May 15, 2024	BUY	$1.3 - $3.58 $127,140 - $350,124	97,800 Added 254.69%	136,200 $326,000
Q4 2023 Feb 14, 2024	BUY	$1.0 - $1.53 $18,900 - $28,917	18,900 Added 96.92%	38,400 $58,000
Q3 2023 Nov 14, 2023	SELL	$1.06 - $2.33 $954 - $2,097	-900 Reduced 4.41%	19,500 $21,000
Q2 2023 Aug 14, 2023	SELL	$2.15 - $3.49 $17,200 - $27,920	-8,000 Reduced 28.17%	20,400 $46,000
Q1 2023 May 15, 2023	BUY	$1.99 - $2.68 $2,388 - $3,216	1,200 Added 4.41%	28,400 $69,000
Q4 2022 Feb 14, 2023	BUY	$1.8 - $2.56 $8,460 - $12,032	4,700 Added 20.89%	27,200 $51,000
Q3 2022 Nov 14, 2022	SELL	$1.94 - $3.43 $6,984 - $12,348	-3,600 Reduced 13.79%	22,500 $54,000

141

238M

459K

133K

Ticker LXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,726,000
Market Cap $162M
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.